Rajaa Tissir, Hanan Rais, Ilyas Tazi
Plasmablastic lymphoma is an aggressive variant of lymphomas recently distinct from diffuse large B cell lymphoma. It has been initially described as a disease affecting the oral cavity of immunocompromised patients. We here report the first case of a 54-year-old patient with nasal septum nodule, bleeding on contact and after sneezing which occurred 6 months before admission. Facial computed tomography (CT) scan showed thickening of the nasal mucosa of 14mm. Excisional biopsy showed tumor proliferation composed of plasmablastic cells with immunophenotypic features: CD 138+, ki67 80%, EMA+, CD79a+, CD 56+...
2020: Pan African Medical Journal
J Vaughan, Y Perner, E Mayne, T Wiggill
OBJECTIVES: Plasmablastic lymphoma (PBL) is a clinically aggressive lymphoma which has a predilection for extranodal sites and is frequently HIV-associated. The incidence of non-Hodgkin lymphoma is thought to be reduced by widescale antiretroviral therapy (ART) coverage, but the literature is sparse as regards the impact of ART on the incidence of PBL and its outcomes in South Africa (SA). This study aimed to compare factors of interest in cases of PBL diagnosed before and after the widespread availability of ART in Johannesburg, SA...
October 6, 2020: HIV Medicine
Andrea Cardenas-Ortega, Ana Florencia Ramírez-Ibarguen, Frida Rivera-Buendía, Carolina Pérez-Jiménez, Patricia Volkow-Fernández, Alexandra Martin-Onraet
The epidemiology of lymphomas has changed since the use of antiretroviral therapy. The incidence of Non-Hodgkin Lymphomas (NHL) has significantly decreased in high income countries but not in low and middle-income countries where AIDS-related events remain high. This observational study describes the characteristics, infectious complications and main outcomes of patients diagnosed with HIV and lymphoma at the Instituto Nacional de Cancerología.All adults >18 years diagnosed with HIV and lymphoma from January 2010 to December 2017 were included...
October 2, 2020: Medicine (Baltimore)
Ren Ching Wang, Yi-Hsiao Chen, Bo-Jung Chen, Shih-Sung Chuang
Lymphomas presenting in effusions could either be primary or secondary, with very limited data from Taiwan. METHODS: We retrospectively reviewed effusion lymphomas from our archives in a tertiary center from July 2011 to June 2019. RESULTS: We identified 59 specimens from 43 patients, including 7 cases with primary effusion lymphoma (PEL) and 36, secondary effusion involvement. Half of the secondary cases presented concurrently with effusion lymphoma, while the remaining half-experienced effusion lymphoma during disease progression...
September 25, 2020: Diagnostic Cytopathology
Samantha Shwe, Aditi A Sharma, Bonnie A Lee, Janellen E Smith
Plasmablastic lymphoma (PBL) is a rare type of non-Hodgkin lymphoma frequently found in the context of immunosuppression and infection with human immunodeficiency virus (HIV) and/or Epstein-Barr virus (EBV). A 33-year-old immunocompetent male presented with recurrent episodes of epistaxis and a growing intranasal mass. Excisional biopsy of the mass revealed an immunohistochemical profile diagnostic of PBL. Upon completion of chemoradiation, he underwent a transnasal endoscopic mucosal flap tissue rearrangement to restore patency for both functional and surveillance purposes...
September 21, 2020: Ear, Nose, & Throat Journal
Leandro Venturutti, Ari Melnick
Activated B-cell (ABC)-Diffuse large B-cell lymphomas (DLBCLs) are clinically aggressive and phenotypically complex malignancies, whose transformation mechanisms remain unclear. Partially differentiated antigen-secreting cells (plasmablasts) have long been regarded as cells-of-origin for these tumors, despite lack of definitive experimental evidence. Recent DLBCL re-classification based on mutational landscapes identified "MCD/C5" tumors as specific ABC-DLBCLs with unfavorable clinical outcome, activating mutations in the signaling adaptors MYD88 and CD79B, and immune evasion through mutation of antigen presenting genes...
September 15, 2020: Blood
Ali F Al Sbihi, Paramveer Singh, Nouraldeen Manasrah, Emad Kandah, Joel Appel
Plasmablastic lymphoma (PBL) is a rare and aggressive B-cell Non-Hodgkin lymphoma (NHL) associated with immunocompromised states such as HIV. We present a case of PBL in an HIV patient presenting as spontaneous tumor lysis syndrome and discuss the clinical challenges hence encountered.
August 9, 2020: Curēus
Tobit D Steinmetz, Ursula Schlötzer-Schrehardt, Abigail Hearne, Wolfgang Schuh, Jens Wittner, Sebastian R Schulz, Thomas H Winkler, Hans-Martin Jäck, Dirk Mielenz
Plasma cells depend on quality control of newly synthesized antibodies in the endoplasmic reticulum (ER) via macroautophagy/autophagy and proteasomal degradation. The cytosolic adaptor protein TFG (Trk-fused gene) regulates ER-Golgi transport, the secretory pathway and proteasome activity in non-immune cells. We show here that TFG is upregulated during lipopolysaccharide- and CpG-induced differentiation of B1 and B2 B cells into plasmablasts, with the highest expression of TFG in mature plasma cells. CRISPR-CAS9-mediated gene disruption of tfg in the B lymphoma cell line CH12 revealed increased apoptosis, which was reverted by BCL2 but even more by ectopic TFG expression...
September 10, 2020: Autophagy
Brenda Mai, Wei Wang, Mei Lin, Shimin Hu, Xiaohong I Wang, Lei Chen, Amer Wahed, Andy Nguyen, Hillary Y Ma, L Jeffrey Medeiros, Zhihong Hu
OBJECTIVES: Patients with HIV infection have an increased risk of developing plasmablastic lymphoma (PBL). In this study, we reviewed the clinicopathologic features of PBL in HIV+ patients in the era of HAART from a single health center. DESIGN: Retrospective study. METHODS: The morphologic, immunophenotypic, and clinical features were reviewed in these HIV+ patients with PBL and univariate analysis was employed to determine the survival prognosis...
October 1, 2020: AIDS
Alexandra C Hristov, Nneka I Comfere, Claudia I Vidal, Uma Sundram
BACKGROUND: Atypical cutaneous lymphoid infiltrates are challenging lesions in dermatopathology. We present a summary of the literature regarding kappa and lambda immunohistochemistry (IHC) and in situ hybridization (ISH) in the evaluation of atypical cutaneous or mucosal lymphoid infiltrates. METHODS: Relevant articles from 1967-2018 in the English language were identified and summarized. In the absence of larger studies, case series of n ≥ 3 were included...
September 1, 2020: Journal of Cutaneous Pathology
Francesca Sanguedolce, Magda Zanelli, Maurizio Zizzo, Giovanni Martino, Cristiana Rossi, Paola Parente, Stefano Ascani
No abstract text is available yet for this article.
August 28, 2020: Pathology, Research and Practice
Daniel Ren Yi Yap, Grace Fangmin Tan, Esther Wei Yin Chang, Valerie Shiwen Yang, Eileen Yi Ling Poon, Nagavalli Somasundaram, Mohamad Farid, Tiffany Tang, Miriam Tao, Soon Thye Lim, Jason Yongsheng Chan
Background: Plasmablastic lymphoma (PBL) is an aggressive subtype of mature B-cell non-Hodgkin lymphoma. Given its rarity, there remains a lack of clinicopathological data to guide its management, particularly on Asian patients. Methods: We conducted a retrospective chart review of 10 patients diagnosed with PBL at the National Cancer Centre Singapore and performed a literature review of similar studies on Asian cohorts. Results: Most patients were male (n = 9), with median age at diagnosis of 55 years (range, 33 - 91 years)...
September 2020: Journal of Hematology (Brossard, Quebec)
Kai Hübel
PURPOSE OF REVIEW: Cancer remains a major cause of morbidity and mortality in HIV-infected individuals, with aggressive non-Hodgkin's lymphoma as the most frequent one. However, the introduction of modern antiretroviral therapy (ART) drastically improved treatment options and prognosis in HIV-associated lymphomas. This review summarized the current treatment landscape and future challenges in HIV-positive patients with non-Hodgkin's and Hodgkin's lymphoma. RECENT FINDINGS: Selecting the appropriate therapy for the individual patient, diffuse-large B cell lymphoma, Burkitt's lymphoma, and Hodgkin's disease may be curable diseases...
August 15, 2020: Current Oncology Reports
Dan Liu, Xiao-Hui He, Yun-Xia Tao, Sheng Yang
Plasmablastic lymphoma(PBL) shows a low incidence and poor prognosis, moreover, there is no standard treatment regimen for PBL. The treatment effect and value of CHOP regimen and radiotherapy are limited. Some studies showed that intensive chemotherapy alone or its combination with proteasome inhibitors or immune regulator can improve the overall survival of patients with PBL, which can be used as the first-line therapy for PBL patients. CAR-T and immunocheckpoint inhibitors showed treatment effect for the patients with refractory and relapsed plasmablastic lymphoma...
August 2020: Zhongguo Shi Yan Xue Ye Xue za Zhi
Jorge A Florindez, Juan Pablo Alderuccio, Isildinha M Reis, Izidore S Lossos
Herein we analyzed survival outcomes in chemotherapy-treated patients with plasmablastic lymphoma (PBL) diagnosed between 2010 to 2016 (n=248). Data was acquired from the Surveillance, Epidemiology, and End Results (SEER) 18 registries database (April 2019 release based on November 2018 submission). The majority of patients were male (81.9%) and younger than 60 years (71.0%). Oral and gastrointestinal (GI) sites were the most frequent primary extranodal locations (23% and 19.4%, respectively). Oral primary location was inversely associated with presence of B-symptoms and advanced Ann-Arbor stage...
August 10, 2020: American Journal of Hematology
Parikshit Padhi, Radwa El-Behery
Extramedullary plasmacytomas (ESPs) are rare forms of plasma cell dyscrasias and usually are seen in the upper aerodigestive tract. ESPs with anaplastic features are extremely rare, and no treatment guidelines exist. We present a 75-year-old gentleman presented with left nasal blockage, and on examination, a polypoid left nasal mass was seen. He was, then, referred to ENT after a CT scan revealed a mass in the left nasopharynx for a biopsy. The preliminary reports suggested a high-grade lymphoma; however, after further testing, it was revealed to be an anaplastic plasma cell neoplasm...
2020: Case Reports in Hematology
Edd Ricker, Akanksha Verma, Rossella Marullo, Sanjay Gupta, Chao Ye, Tania Pannellini, Michela Manni, Wayne Tam, Giorgio Inghirami, Olivier Elemento, Leandro Cerchietti, Alessandra B Pernis
Activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) is an aggressive subtype of lymphoma usually associated with inferior outcomes. ABC-DLBCL exhibits plasmablastic features and is characterized by aberrancies in the molecular networks controlled by IRF4. The signaling pathways that are dysregulated in ABC-DLBCL are, however, not fully understood. ROCK2 is a serine-threonine kinase whose role in lymphomagenesis is unknown. Here we show that ROCK2 activity is constitutively dysregulated in ABC-DLBCL but not in GCB-DLBCL and BL...
August 4, 2020: Scientific Reports
Nadhirah Mohd Shakri, Salina Husain, Farah Dayana Zahedi, Geok Chin Tan
Plasmablastic lymphoma (PBL) is a rare and aggressive variant of diffuse large B-cell lymphoma predominantly in oral cavities of human immunodeficiency virus (HIV)-positive male patients or immunosuppressive hosts. Limited number of reports on HIV-negative PBL in immunocompetent patients are available in the literature. We reported an unusual case of sinonasal PBL which occurred in an HIV-negative and immunocompetent female patient. She underwent endoscopic removal of the tumor and completed 6 cycles of chemotherapy (hyperfractionated-CVAD)...
2020: Medeniyet medical journal
Brenda Mai, Wei Wang, Mei Lin, Shimin Hu, Xiaohong Iris Wang, Lei Chen, Amer Wahed, Andy Nguyen, Hillary Y Ma, L Jeffrey Medeiros, Zhihong Hu
OBJECTIVES: Patients with human immunodeficiency virus (HIV) infection have an increased risk of developing plasmablastic lymphoma (PBL). In this study, we reviewed the clinicopathologic features of PBL in HIV+ patients in the era of highly active anti-retroviral therapy (HAART) from a single health center. DESIGN: Retrospective study. METHODS: The morphologic, immunophenotypic and clinical features were reviewed in these HIV+ patients with PBL and univariate analysis was employed to determine the survival prognosis...
July 21, 2020: AIDS
Blessie Nelson, Angelina Hong, Fatima Iqbal, Rohit Venkatesan
Plasmablastic lymphoma (PBL) is a rare form of non-Hodgkin lymphoma that is highly aggressive and carries a poor prognosis. Although the standard chemotherapy choice for most diffuse large B-cell lymphomas (DLBCL) is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), subtypes of DLBCL such as PBL are less responsive to this treatment regimen. The preferred regimens for PBL include infusional EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride), HyperCVAD (cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone), or CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine)...
June 15, 2020: Curēus
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"